5-Formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively

Daniel Gackowski, Maciej Gawronski, Cassandra Kerr, Tomas Radivoyevitch, Ewelina Zarakowska, Marta Starczak, Abdulkadir Abakir, Alexey Ruzov, Jaroslaw P. Maciejewski, and Ryszard Olinski

Disclosures: This work was supported in parts by the Polish National Science Center (www.ncn.gov.pl) grants: UMO-2015/19/B/NZ5/02208 to D. G. and UMO-2017/27/B/NZ7/01487 to R.O; by National Institutes of Health (Bethesda, MD; NIH) grants, R01HL123904, R01HL132071, R35HL135795 to J.P.M; by Medical Research Council IMPACT DTP PhD Studentship (grant number MR/N013913/1) to A.A and by Biotechnology and Biological Sciences Research Council (grant number BB/N005759/1) to A.R.

Contributions: D.G. performed UPLC/MS/MS analyses, collected and analyzed data, prepared the manuscript and provided funding support; M.G. prepared samples for UPLC/MS/MS analyses, collected and analyzed data, edited the manuscript; C.K. contributed patients, provided bone marrow samples and clinical data; T. R. contributed patients and data, performed analyses of patients mutational status, and reviewed the manuscript; E.Z. prepared samples for UPLC/MS/MS analyses, collected and analyzed data; M.S. prepared samples for UPLC/MS/MS analyses, collected and analyzed data; A.A. performed cell culture experiments, provided funding support; A.R. performed cell culture experiments, contributed to study design, data analysis, reviewed the manuscript and provided funding support; J.P.M. provided study design, contributed patients and reviewed and edited the manuscript; R.O. provided study design, wrote the manuscript and provided funding support; and all authors read and approved the final manuscript.